1. Home
  2. ALT
  3. ALT News

Latest Altimmune Inc. (ALT) News on November 6, 2025

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
ALT

GlobeNewswire

3 days ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

3 Explosive Stocks With High Short Interest
ALT

24/7 Wall St.

6 days ago

3 Explosive Stocks With High Short Interest

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
ALT

GlobeNewswire

7 days ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Pleasing Signs As A Number Of Insiders Buy Altimmune Stock
ALT

Simply Wall St.

a month ago

Pleasing Signs As A Number Of Insiders Buy Altimmune Stock

Altimmune to Participate in Two Upcoming Investor Conferences
ALT

GlobeNewswire

a month ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
ALT

GlobeNewswire

4 months ago

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial
ALT

Insider Monkey

4 months ago

Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial

ALT

MT Newswires

4 months ago

Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
ALT

GlobeNewswire

4 months ago

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
ALT

GlobeNewswire

4 months ago

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
ALT

GlobeNewswire

5 months ago

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
ALT

GlobeNewswire

6 months ago

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
ALT

TipRanks

6 months ago

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

Altimmune to Participate at Two Upcoming Investor Conferences
ALT

GlobeNewswire

6 months ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
ALT

GlobeNewswire

6 months ago

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

Altimmune Announces First Quarter 2025 Financial Results and Business Update
ALT

GlobeNewswire

6 months ago

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
ALT

GlobeNewswire

6 months ago

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
ALT

GlobeNewswire

6 months ago

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
ALT

GlobeNewswire

6 months ago

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

Altimmune to Participate in the Citizens Life Sciences Conference
ALT

GlobeNewswire

6 months ago

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune's US$42m Market Cap Fall Books Insider Losses
ALT

Simply Wall St.

7 months ago

Altimmune's US$42m Market Cap Fall Books Insider Losses

Altimmune to Host Virtual R&D Day on March 13, 2025
ALT

GlobeNewswire

8 months ago

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Participate in the Leerink Global Healthcare Conference
ALT

GlobeNewswire

8 months ago

Altimmune to Participate in the Leerink Global Healthcare Conference

Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
ALT

Simply Wall St.

8 months ago

Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
ALT

GlobeNewswire

8 months ago

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
ALT

GlobeNewswire

8 months ago

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
ALT

GlobeNewswire

9 months ago

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns
ALT

Simply Wall St.

9 months ago

With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
ALT

GlobeNewswire

9 months ago

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
ALT

Simply Wall St.

10 months ago

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune Added to Nasdaq Biotechnology Index
ALT

GlobeNewswire

a year ago

Altimmune Added to Nasdaq Biotechnology Index

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
ALT

GlobeNewswire

a year ago

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Altimmune to Participate at Two Upcoming Investor Conferences
ALT

GlobeNewswire

a year ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
ALT

GlobeNewswire

a year ago

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations
ALT

Simply Wall St.

a year ago

Altimmune Third Quarter 2024 Earnings: Beats Expectations

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
ALT

GlobeNewswire

a year ago

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
ALT

GlobeNewswire

a year ago

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ALT

GlobeNewswire

a year ago

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
ALT

GlobeNewswire

a year ago

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Altimmune to Participate at Two Upcoming Investor Conferences
ALT

GlobeNewswire

a year ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
ALT

GlobeNewswire

a year ago

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
ALT

GlobeNewswire

a year ago

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
ALT

GlobeNewswire

a year ago

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALT

GlobeNewswire

a year ago

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
ALT

GlobeNewswire

a year ago

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
ALT

GlobeNewswire

a year ago

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
ALT

GlobeNewswire

a year ago

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags
ALT

Simply Wall St.

a year ago

Altimmune First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
ALT

GlobeNewswire

a year ago

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
ALT

GlobeNewswire

a year ago

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing
ALT

Simply Wall St.

a year ago

With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
ALT

GlobeNewswire

a year ago

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
ALT

GlobeNewswire

a year ago

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Altimmune to Participate at Leerink Partners Therapeutics Forum
ALT

GlobeNewswire

a year ago

Altimmune to Participate at Leerink Partners Therapeutics Forum

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
ALT

GlobeNewswire

a year ago

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt

Crypto under pressure, Good Buy or Goodbye: Market Domination
ALT

Yahoo Finance Video

a year ago

Crypto under pressure, Good Buy or Goodbye: Market Domination

Altimmune reports positive results in weight-loss drug trial
ALT

Yahoo Finance Video

a year ago

Altimmune reports positive results in weight-loss drug trial

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
ALT

GlobeNewswire

a year ago

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
ALT

GlobeNewswire

a year ago

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
ALT

Simply Wall St.

a year ago

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
ALT

GlobeNewswire

a year ago

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
ALT

GlobeNewswire

a year ago

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
ALT

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

ALT

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
ALT

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
ALT

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
ALT

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips
ALT

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
ALT

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
ALT

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Lotto 6/49 - $64 million up for grabs in the next draw!
ALT

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
ALT

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
ALT

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
ALT

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
ALT

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
ALT

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
ALT

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
ALT

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

ALT

Business Wire

a year ago

Net Asset Value(s)

CCF Group Successful €225m AT1 Issuance
ALT

Business Wire

a year ago

CCF Group Successful €225m AT1 Issuance

Should You Hold 908 Devices (MASS)?
ALT

Insider Monkey

a year ago

Should You Hold 908 Devices (MASS)?

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028
ALT

GlobeNewswire

a year ago

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

3 Major Product Releases at 3Shape Discover Event
ALT

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Calculating The Fair Value Of Mincon Group plc (LON:MCON)
ALT

Simply Wall St.

a year ago

Calculating The Fair Value Of Mincon Group plc (LON:MCON)

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens
ALT

GlobeNewswire

a year ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029
ALT

GlobeNewswire

a year ago

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALT

GlobeNewswire

a year ago

Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Altimmune to Participate at Two Upcoming Investor Conferences
ALT

GlobeNewswire

a year ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
ALT

GlobeNewswire

a year ago

Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
ALT

PR Newswire

a year ago

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)
ALT

Simply Wall St.

a year ago

Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
ALT

GlobeNewswire

a year ago

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Altimmune to Participate at Two Upcoming Investor Conferences
ALT

GlobeNewswire

a year ago

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
ALT

GlobeNewswire

2 years ago

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Altimmune to Participate at Two Upcoming Conferences
ALT

GlobeNewswire

2 years ago

Altimmune to Participate at Two Upcoming Conferences

Altimmune Statement on the Passing of Dr. Stephen Harrison
ALT

GlobeNewswire

2 years ago

Altimmune Statement on the Passing of Dr. Stephen Harrison

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
ALT

GlobeNewswire

2 years ago

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
ALT

GlobeNewswire

2 years ago

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

Chuck Royce Increases Stake in SecureWorks Corp
ALT

GuruFocus.com

2 years ago

Chuck Royce Increases Stake in SecureWorks Corp

Pest Control Market Analysis Report 2023: Chemical, Mechanical, Biological, Software & Services, Sprays, Traps, Baits, Pellets, Powder - Global Forecast to 2028
ALT

GlobeNewswire

2 years ago

Pest Control Market Analysis Report 2023: Chemical, Mechanical, Biological, Software & Services, Sprays, Traps, Baits, Pellets, Powder - Global Forecast to 2028

Share on Social Networks: